Major depressive disorders, long considered to be of neurochemical origin, have recently
been associated with impairments in signaling pathways that regulate neuroplasticity and …

The limited success of genetic studies of major depression has raised questions concerning
the definition of genetically relevant phenotypes. This paper presents strategies to improve …

Mood disorders are common, chronic, recurrent mental illnesses that affect the lives of
millions of individuals worldwide. To date, the monoaminergic systems (serotonergic …

Background Concerns regarding potential neurological complications of COVID-19 are
being increasingly reported, primarily in small series. Larger studies have been limited by …

Preliminary clinical data indicate that severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection is associated with neurological and neuropsychiatric illness …

Context Existing therapies for major depression have a lag of onset of action of several
weeks, resulting in considerable morbidity. Exploring pharmacological strategies that have …

BACKGROUND: Ketamine exerts a robust, rapid, and relatively sustained antidepressant
effect in patients with major depression. Understanding the mechanisms underlying the …

The'neurotrophin hypothesis of depression'is based largely on correlations between stress
or antidepressant treatment and down-or upregulation, respectively, of brain-derived …

Context Existing therapies for bipolar depression have a considerable lag of onset of action.
Pharmacological strategies that produce rapid antidepressant effects—for instance, within a …

Increasing evidence suggests that mood disorders are associated with a reduction in
regional CNS volume and neuronal and glial cell atrophy or loss. Lithium, a mainstay in the …